Revive Therapeutics Ltd. (31R.F)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Michael Frank | Chairman & CEO | 245.84k | -- | 1961 |
Mr. Carmelo Marrelli ACIS, B.Comm., C.A., CGA, CPA | Chief Financial Officer | 88.85k | -- | 1971 |
Dr. Kelly T. McKee Jr., M.D., M.P.H. | Chief Scientific Officer Consultant | -- | -- | 1951 |
Dr. Onesmo Mpanju Ph.D. | Chief Regulatory Affairs Consultant | -- | -- | -- |
Revive Therapeutics Ltd.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Description
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. The company is based in Toronto, Canada.
Corporate Governance
Recent Events
Recent Events Information Not Available